The study of Yoshimura (2013) in which patients with NSCLC and an EGFR mutation who previously were treated with EGFR-TKIs and in the trial were treated with pemetrexed in combination with erlotinib or gefitinib had disease control rate as primary outcome. This evidence concerns the gene EGFR and non-small cell lung carcinoma.